- Home
- CUK vs ALNY Comparison
CUK vs ALNY Comparison
Compare CUK & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUK
- ALNY
- Stock Information
- Founded
- CUK 1972
- ALNY 2002
- Country
- CUK United States
- ALNY United States
- Employees
- CUK N/A
- ALNY N/A
- Industry
- CUK Marine Transportation
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- CUK Consumer Discretionary
- ALNY Health Care
- Exchange
- CUK Nasdaq
- ALNY Nasdaq
- Market Cap
- CUK 27.8B
- ALNY 35.0B
- IPO Year
- CUK 2000
- ALNY 2004
- Fundamental
- Price
- CUK $17.53
- ALNY $238.74
- Analyst Decision
- CUK Buy
- ALNY Buy
- Analyst Count
- CUK 19
- ALNY 23
- Target Price
- CUK $26.68
- ALNY $310.86
- AVG Volume (30 Days)
- CUK 2.1M
- ALNY 735.1K
- Earning Date
- CUK 03-21-2025
- ALNY 05-01-2025
- Dividend Yield
- CUK N/A
- ALNY N/A
- EPS Growth
- CUK N/A
- ALNY N/A
- EPS
- CUK 1.44
- ALNY N/A
- Revenue
- CUK $25,021,000,000.00
- ALNY $2,248,243,000.00
- Revenue This Year
- CUK $7.32
- ALNY $31.04
- Revenue Next Year
- CUK $4.02
- ALNY $23.56
- P/E Ratio
- CUK $12.94
- ALNY N/A
- Revenue Growth
- CUK 15.88
- ALNY 22.97
- 52 Week Low
- CUK $12.50
- ALNY $141.98
- 52 Week High
- CUK $26.14
- ALNY $304.39
- Technical
- Relative Strength Index (RSI)
- CUK 23.96
- ALNY 39.81
- Support Level
- CUK $19.56
- ALNY $238.42
- Resistance Level
- CUK $22.14
- ALNY $252.84
- Average True Range (ATR)
- CUK 1.02
- ALNY 9.28
- MACD
- CUK -0.45
- ALNY -1.07
- Stochastic Oscillator
- CUK 11.60
- ALNY 30.80
About CUK Carnival Plc ADS ADS
Carnival is the largest global cruise company, with more than 90 ships in service at the end of fiscal 2024. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America; P&O Cruises and Cunard Line in the United Kingdom; Aida in Germany; Costa Cruises in Southern Europe. It's currently folding its P&O Australia brand into Carnival. The firm also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted 14 million guests in 2024.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.